Good to read an update on the Vitiligo program. CUV regular team finalizing scientific data to be presented at the FDA's DDDP, which is the same Division that reviewed and approved SCENESSE. Considerable advantage as it is the reviewers. CUV to report on Vitiligo shortly and their approach tot he relatively uncharted medical indication Vitiligo will be similar to how the UV team approached EPP in 2006.
$1.64B company.
Ann: CLINUVEL Newsletter, page-2
-
- There are more pages in this discussion • 6 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add CUV (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$14.76 |
Change
0.165(1.13%) |
Mkt cap ! $739.1M | |||
| Open | High | Low | Value | Volume |
| $14.76 | $14.96 | $14.46 | $802.4K | 54.57K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 4 | 145 | $14.73 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $14.77 | 200 | 13 |
View Market Depth
| Last trade - 13.49pm 31/07/2024 (20 minute delay) ? |
| CUV (ASX) Chart |